Interferon-stimulated gene 15 and ISGylation are upregulated in glioblastoma.


Journal

Biochemical and biophysical research communications
ISSN: 1090-2104
Titre abrégé: Biochem Biophys Res Commun
Pays: United States
ID NLM: 0372516

Informations de publication

Date de publication:
17 09 2022
Historique:
received: 01 06 2022
revised: 22 06 2022
accepted: 04 07 2022
pubmed: 15 7 2022
medline: 6 8 2022
entrez: 14 7 2022
Statut: ppublish

Résumé

Interferon stimulated gene 15 (ISG15) encodes a 15-kDa ubiquitin-like protein that acts as a posttranslational modifier of target proteins via ISGylation, a catalytic process similar to ubiquitination. Protein ISGylation is associated with the modulation of protein stability and protein-protein interactions. Furthermore, non-conjugated ISG15 (free ISG15) is secreted to act as a cytokine-like protein in some cellular contexts. The expression of ISG15 in some cancer types is dysregulated, but its expression status in glioblastoma, a malignant brain tumor highly aggressive and invasive, requires more studies. To explore the potential of ISG15 as a biomarker for glioblastoma, we first evaluated the ISG15 levels in glioblastoma cell lines and the effect of IFN-γ treatment on protein levels and localization of ISG15. In addition, we analyzed the ISG15 levels in glioblastoma samples compared to healthy brain tissue. Our results indicate that ISG15 levels are increased in glioblastoma and are upregulated in response to IFN-γ stimulus, suggesting that ISG15 and ISGylation may play a central role in glioblastoma progression. Thus, ISG15/ISGyaltion may be useful as biomarkers of this type of malignant brain tumors.

Identifiants

pubmed: 35834923
pii: S0006-291X(22)00972-X
doi: 10.1016/j.bbrc.2022.07.011
pii:
doi:

Substances chimiques

Antiviral Agents 0
Cytokines 0
Ubiquitins 0
Interferons 9008-11-1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

144-150

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare no conflict of interest.

Auteurs

Angeles C Tecalco-Cruz (AC)

Posgrado en Ciencias Genómicas, Universidad Autónoma de la Ciudad de México (UACM), Apdo, 03100, Ciudad de México, Mexico. Electronic address: angeles.tecalco@uacm.edu.mx.

Gabriela Velasco-Loyden (G)

Instituto de Fisiología Celular, UNAM, Apdo, 04510, Ciudad de México, Mexico.

Lucero Robles-Villarruel (L)

Posgrado en Ciencias Genómicas, Universidad Autónoma de la Ciudad de México (UACM), Apdo, 03100, Ciudad de México, Mexico.

Carlo César Cortes-González (CC)

Unidad de Investigación Biomédica en Cáncer, INCAN-Instituto de Investigaciones Biomédicas, Tlalpan, C.P. 14080, México City, Mexico.

Jesús Zepeda-Cervantes (J)

Facultad de Medicina Veterinaria y Zootecnia. Departamento de Microbiología e Inmunología. UNAM, Apdo, 04510, Ciudad de México, Mexico.

Benjamín Pineda (B)

Instituto Nacional de Neurología y Neurocirugía. Laboratorio de Neuroinmunología, Apdo, 14269, Ciudad de México, Mexico.

Victoria Chagoya de Sánchez (V)

Instituto de Fisiología Celular, UNAM, Apdo, 04510, Ciudad de México, Mexico.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH